|
Tercica, Inc.Published by: Datamonitor Published: Aug. 15, 2007 - 28 Pages Table of Contents
AbstractDatamonitor's Tercica, Inc. Company Profile is the essential source for top-level company data and information. The report examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.Tercica is a biopharmaceutical company engaged in developing and marketing a portfolio of endocrinology products. The company partners with the scientific and medical community to develop and commercialize therapeutics for growth and other endocrine disorders. The company primarily operates in the US. The company is headquartered in Brisbane, California and employs about 100 people. The company recorded revenues of $1.5 million in 2006. The company did not report any revenues during 2005, as it began commercializing Increlex, the sole marketed product, only in 2006. The operating loss of the company was $86.4 million during fiscal year 2006, as compared to an operating loss of $47.5 million in 2005. The increase in operating loss as compared to fiscal 2005 was primarily due to increase in the operating expenses owing to the launch of Increlex. The net loss was $82.9 million in fiscal year 2006, as compared to a net loss of $46.2 million in 2005. Scope of the Report
Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||